A large percentage of DLB patients have both Aβ and α-synuclein oligomers present in the brain. Zervimesine (also CT1812) has the potential to slow the progression of both Alzheimer’s disease and DLB by acting to prevent the buildup of the toxic Aβ oligomers that drive Alzheimer’s disease and the harmful α-synuclein oligomers responsible for DLB.
Only a few symptomatic treatments (to control agitation) for dementia with Lewy bodies are approved today, and at present, no disease-modifying therapeutics exist for these patients. Cognition Therapeutics conducting SHIMMER, a Phase 2 clinical trial investigating whether zervimesine has a beneficial effect in adults diagnosed with mild to moderate DLB. The study was supported by a grant awarded by the National Institute of Aging (part of the National Institutes of Health).
DEMENTIA WITH LEWY BODIES
- Day-to-day fluctuations in alertness level
- Auditory and visual hallucinations, often of children or animals
- Delusions
- Resting tremors and movement disorders (shuffling gait)
- REM sleep disorder (acting out dreams while sleeping)
- Complete with results: 130 adults with mild-to-moderate dementia with Lewy bodies (DLB) were randomized to receive one of two doses of zervimesine or placebo for six months.
- Supported by a $30 million grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH).
- On December 18, 2024, a webcast was held to review topline results from the SHIMMER study. Click here for the archive.
- For more information, please visit clinicaltrials.gov and reference study ID NCT05225415.